Every material Form 8-K Alto Ingredients, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alto Ingredients reported third-quarter 2026 results on November 4, 2026. Net sales rose to $257.9 million from $241.0 million, but gross profit fell to $14.8 million from $23.5 million, and net income attributable to common stockholders fell to $12.7 million, or $0.16 per diluted share, from $13.9 million, or $0.19. The company credited $7.6 million of net transferable tax credits for part of the quarter's result, which shareholders may weigh against the weaker operating profit.
Q3 2026 net sales were $257.9 million, compared with $241.0 million in Q3 2025.
Q3 2026 gross profit was $14.8 million, compared with $23.5 million; adjusted EBITDA was $21.0 million, compared with $21.4 million.
Q3 2026 net income attributable to common stockholders was $12.7 million, or $0.16 per diluted share, compared with $13.9 million, or $0.19 per share.
The company expects to generate a minimum of $20 million, net of monetization costs, in 2026 from 45Z tax credits.
Alto Ingredients entered an at-the-market sales agreement on August 5, 2026, allowing it to sell up to $50.0 million of common stock through three sales agents over time. The company is not obligated to sell any shares, and any sales would add to the outstanding share count, which could dilute existing shareholders.
Program covers up to $50.0 million of common stock at an aggregate offering price, sold through Craig-Hallum Capital Group LLC, The Benchmark Company, LLC and H.C. Wainwright & Co., LLC
Company pays the agents a 3.0% commission on aggregate gross proceeds, plus certain expenses
Shares are issued under a Form S-3 shelf registration declared effective May 22, 2026, with a prospectus supplement filed August 5, 2026
Net proceeds, if any, are intended for general corporate purposes, including working capital and capital expenditures
Alto Ingredients reported second quarter 2026 net income attributable to common stockholders of $11.4 million, or $0.15 per diluted share, compared with a net loss of $11.3 million in the prior-year quarter. The company also established a $50 million at-the-market equity program, which gives it a way to sell new shares to fund future projects if it chooses.
Q2 2026 net sales were $245.7 million, up from $218.4 million; gross profit was $16.6 million versus a gross loss of $1.9 million
Q2 2026 adjusted EBITDA was $23.7 million, compared with negative $0.2 million a year earlier
Company established a $50 million at-the-market equity program; June 30, 2026 borrowing availability was $106 million
Net income for Q2 2026 included $5.1 million in transferable tax credits, net
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alto Ingredients, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →